1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Complex Generics: Pre-Competitive Research Collaborations To Get US FDA Funding Boost

 
• By Derrick Gingery

Center for Research on Complex Generics will be similar to the Critical Path Institute; training sessions for industry could begin in January.

Complexity (Michael D Brown/Shutterstock.com)
The FDA is funding an academic center intended to promote pre-competitive industry collaboration on complex generic development. • Source: Shutterstock

The US Food and Drug Administration is hoping an academic-run group can boost industry’s involvement in complex generic drug research.

A five-year, $5m grant to the University of Maryland and University of Michigan will establish the Center for Research...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Aurobindo, MSN Fail To Beat US Nuplazid Patent Expiring In August 2038

 
• By Dean Rudge

Acadia’s Nuplazid for hallucinations and delusions associated with Parkinson’s disease psychosis appears safe from generic competition until well into the next decade, following a favorable infringement and validity decision by a US district court.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

More from Biosimilars & Generics